Specify a stock or a cryptocurrency in the search bar to get a summary
Glaukos Corp
GKOSGlaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. Address: One Glaukos Way, Aliso Viejo, CA, United States, 92656
Analytics
WallStreet Target Price
141.67 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures GKOS
Dividend Analytics GKOS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History GKOS
Stock Valuation GKOS
Financials GKOS
Results | 2019 | Dynamics |